Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?

Gladdy, Rebecca A.; Qin, Li‐Xuan; Moraco, Nicole H.; Edgar, Mark A.; Antonescu, Cristina R.; Alektiar, Kaled M.; Brennan, Murray F.; Singer, Samuel

doi:10.1200/jco.2009.25.1728

Cited by 257 publications

(249 citation statements)

References 27 publications

Supporting

Mentioning

230

Contrasting

Unclassified

Order By: Relevance

“…Although most radiation-associated sarcomas can be classified as undifferentiated pleomorphic sarcoma, angiosarcoma, or leiomyosarcoma, 25 3 tumor types with frequent alternative lengthening of telomeres, only 3 of the 15 radiation-associated sarcomas were alternative lengthening of telomeres positive (20%), and none was ATRX deficient.…”

Section: Alternative Lengthening Of Telomeres and Loss Of Atrx Expresmentioning

confidence: 99%

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

et al. 2015

View full text Add to dashboard Cite

According to cytogenetic aberrations, sarcomas can be categorized as complex or simple karyotype tumors. Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas. Recently, this mechanism was found to be associated with loss of either α-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain-associated (DAXX) protein. We previously reported that alternative lengthening of telomeres and loss of ATRX expression were common in leiomyosarcoma, angiosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma. In the present study, we screened an additional 245 sarcomas of other types to determine the prevalence of alternative lengthening of telomeres, loss of ATRX/DAXX expression, and their relationship. Undifferentiated pleomorphic sarcomas were frequently alternative lengthening of telomeres positive (65%) and loss of ATRX was seen in approximately half of the alternative lengthening of telomeres-positive tumors. Nineteen of 25 myxofibrosarcomas were alternative lengthening of telomerespositive, but only one was ATRX deficient. Three of 15 radiation-associated sarcomas were alternative lengthening of telomeres positive, but none of them was ATRX deficient. Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas. By contrast, none of the 71 gene fusion-associated sarcomas was ATRX deficient or alternative lengthening of telomeres positive. All tumors exhibited preserved DAXX expression. Combining our previous studies and this study, a total of 384 sarcomas with complex karyotypes were examined, 83 of which were ATRX deficient (22%). By telomere-specific fluorescence in situ hybridization, 45% (138/308) were alternative lengthening of telomeres positive, 55% (76/138) of which were ATRX deficient. Loss of ATRX was highly associated with alternative lengthening of telomeres (Po 0.001). We conclude that alternative lengthening of telomeres is a frequent telomere-maintenance mechanism in cytogenetically complex sarcomas. Loss of ATRX is highly associated with this feature.

show abstract

Section: Alternative Lengthening Of Telomeres and Loss Of Atrx Expresmentioning

confidence: 99%

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The prognosis for patients with RAS is poor and is comparable to the prognosis for patients with sporadic soft tissue sarcoma according to most authors, although Gladdy et al reported a worse prognosis for 130 patients who had RAS compared with their entire cohort of >7000 patients who had sporadic soft tissue sarcomas. 3,4,8 This may be because of a higher rate of incomplete resections caused by multifocal disease and the less frequent use of adjuvant radiotherapy for patients with RAS in their series. 8 The median latency period ranges from 59 to 103 months in the literature, which is in line with our data.…”

Section: Discussionmentioning

confidence: 99%

Reirradiation and hyperthermia for radiation‐associated sarcoma

Jong

Oldenborg

Oei

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to evaluate the role of reirradiation and hyperthermia in the treatment of radiation-associated sarcoma (RAS) in the thoracic region, which is an increasing, yet extremely rare condition with a poor prognosis. METHODS: Between 1979 and 2009, 16 patients with RAS in the thoracic region were treated in the Academic Medical Center and the Institute Verbeeten with reirradiation and hyperthermia. In 13 patients, this treatment was given for unresectable disease and 3 times after resection as adjuvant treatment. The median latency period between the original malignancy diagnosis and the RAS diagnosis was 86 months (range 19-212 months). Histology was angiosarcoma in 11 patients (69%). The literature on reirradiation with or without hyperthermia for RAS was reviewed. RESULTS: The median survival was 15.5 months (range, 3-204 months). Four patients were not evaluable for response. The response rate for the remaining 12 patients was 75% (7 complete responses and 2 partial responses). Six patients remained free of local failure until death (5 months and 7 months) or last follow-up (8 months, 11 months, 39 months, and 68 months). CONCLUSIONS: The current study indicates that combined reirradiation and hyperthermia for RAS in the thoracic region is feasible. The high response rate and the possibility of durable local control suggest that this treatment is promising. Cancer 2012;118:180-

show abstract

“…Радиоиндуцированные саркомы мягких тканей со-ставляют 0,45-2,5% от общего числа впервые диагно-стированных сарком мягких тканей [1][2][3]. Наиболее информативные данные были представлены Memorial Sloan-Kettering Cancer Center (2010), согласно которым за период с 1982 по 2007 г. среди 7649 наблюдений сарком мягких тканей, зарегистрированных в центре, лишь 130 (1,6%) являлись радиоиндуцированными [2].…”

unclassified

“…Наиболее информативные данные были представлены Memorial Sloan-Kettering Cancer Center (2010), согласно которым за период с 1982 по 2007 г. среди 7649 наблюдений сарком мягких тканей, зарегистрированных в центре, лишь 130 (1,6%) являлись радиоиндуцированными [2].…”

unclassified

“…В среднем латентный период составляет 14 лет [6]. Однако, согласно опублико-ванным в 2010 г. данным, саркомы мягких тканей можно признать радиоиндуцированными, если их обнаруживают спустя 6 мес после лучевой терапии [2].…”

unclassified

See 1 more Smart Citation

Radiation-induced pleural fibrosarcoma in a female patient 25 years after treatment for thymoma

Trakhtenberg¹,

Амиралиев²,

Khmelevsky³

et al. 2016

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

The paper describes a clinical case of surgical treatment in a female patient with radiation-induced pleural fibrosarcoma. in 1990 due to lymphoepithelial thymoma, she underwent anterior superior mediastinal mass removal, followed by radiotherapy in a total focal dose of 60 Gy. 25 years later, an examination revealed an anterior superior mediastinal mass, a morphological examination diagnosed fibrosarcoma G2.

show abstract

Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?

Cited by 257 publications

References 27 publications

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

Reirradiation and hyperthermia for radiation‐associated sarcoma

Radiation-induced pleural fibrosarcoma in a female patient 25 years after treatment for thymoma

Contact Info

Product

Resources

About